Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAK Cells for Malignant Pleural and Peritoneal Effusion
NCT05565014Phase 1Unknown
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Virus Activated Killer Immune Cells in malignant pleural effusion (MPE) and malignant ascites (2 arms). Primary endpoint: Incidence of Adverse Events and Serious Adverse Events. Status: unknown.
02
Drugs
Virus Activated Killer Immune Cells
03
Conditions
malignant pleural effusion (MPE)malignant ascites
Beyond the preview
Go deeper on NCT05565014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565014.